Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Endocrine Cancers: Pathophysiology and Therapy
share announcement

Endocrine Cancers: Pathophysiology and Therapy

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 664

Special Issue Editors

Dr. Rajeev Parameswaran

E-Mail Website
Guest Editor
Department of Surgery, Yong Loo Lin School of Medicine, Level 8. IE Kent Ridge Road, Singapore 119228, Singapore
Interests: endocrine cancers; aberrant glycans
Special Issues, Collections and Topics in MDPI journals
Dr. Amit Agrawal

E-Mail Website
Guest Editor
Director, Department of Endocrine and Breast Surgery, Medanta Hospital, Lucknow, India
Interests: endocrine cancers; thyroid; parathyroid and adrenal tumours; paraganglioma

Special Issue Information

Dear Colleagues,

There has been significant progress made in the understanding of cancers affecting the endocrine glands, namely the thyroid, parathyroid, adrenal, and neuroendocrine glands, as a result of genome, epigenome, and transcriptome analyses. This knowledge has paved the way for precision and personalized treatments for patients with endocrine cancers of both sporadic and inheritable origins. In the field of thyroidology, preoperative molecular markers have enabled preoperative detection of cancer in nodules considered indeterminate with fair accuracy, thereby avoiding unnecessary surgery. Molecular and pathway analysis has allowed for better prognostic classification and response prediction for targeted therapies, especially for multikinase inhibitors. Genetic dissection of adrenal cancers and paragangliomas has revealed the roles played by IGF and WNT signalling pathways in the pathogenesis of these aggressive tumours, but not much progress has been made in the treatment of advanced disease, especially when metastasis develops.

In this Special Issue, we aim to focus on the molecular pathways and targeted therapies that include basic science, preclinical, and translational studies in the management of endocrine cancers.

Dr. Rajeev Parameswaran
Dr. Amit Agrawal
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thyroid
  • parathyroid
  • adrenal
  • paraganglioma
  • genomes
  • transcriptomes
  • signalling pathways
  • precision medicine

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1859 KiB  
Article
Nearly Half of Patients with Anaplastic Thyroid Cancer May Be Amenable to Immunotherapy
by Beverley Chern, Diluka Pinto, Jeffrey Hy Lum and Rajeev Parameswaran
Biomedicines 2024, 12(6), 1304; https://doi.org/10.3390/biomedicines12061304 - 12 Jun 2024
Viewed by 502
Abstract
Importance: Poorly differentiated cancer (PDC) and anaplastic thyroid cancer (ATC) have an aggressive course of disease with limited treatment options. The expression of programmed cell death ligand-1 (PD-L1) has been used to determine the responses of many cancers to immunotherapy. The aim of [...] Read more.
Importance: Poorly differentiated cancer (PDC) and anaplastic thyroid cancer (ATC) have an aggressive course of disease with limited treatment options. The expression of programmed cell death ligand-1 (PD-L1) has been used to determine the responses of many cancers to immunotherapy. The aim of the study was to investigate the expression of PD-L1 in a cohort of patients with PDC and ATC to assess their suitability for immunotherapy. Data, settings, and participants: This study is a retrospective cohort review of patients treated for PDC and ATC treated at a tertiary referral institution during the period 2000–2020. PD-L1 22C3 pharmDx qualitative immunohistochemistry was performed on formalin-fixed, paraffin-embedded (FFPE) specimens of tumours to detect the presence of the PD-L1 protein. Main outcome measures: The percentage of tumours that were positive for PD-L1 immunohistochemistry and the PD-L1 protein expression as measured by using the Tumour Proportion Score (TPS). Secondary outcomes studied were the associations between demographic, clinicopathological, treatment and disease outcomes and PD-L1 expression. Results: Nineteen patients (12F:7M) with a mean age of 65.4 (±14.3 SD) years were diagnosed with PDC in 4 (21%) and fifteen were diagnosed with ATC (79%) during the study period. Fifteen (79%) patients underwent some form of surgery, with R0 resection achieved in only three of the fifteen (20%) patients. Overall, PD-L1 expression was seen in seven of the fifteen (47%) of the patients with ATC, with no positivity seen in the patients with PDC. PD-L1 expression had no impact on treatment modality and positive expression was not significantly associated with stage of disease, metastasis, or survival. Conclusion: Nearly half of patients with ATC express PD-L1 and may be amenable to immunotherapy with pembrolizumab. Full article
(This article belongs to the Special Issue Endocrine Cancers: Pathophysiology and Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop